The World Health Organization (WHO) has issued a fresh draft of its biosimilar evaluation guidelines. Medicines for Europe science and policy expert Marta Baldrighi, PhD, explains the significance.
The Center for Biosimilars® spoke recently with Marta Baldrighi, PhD, policy and science officer for Medicines for Europe, a trade organization of generics and biosimilars producers, about the World Health Organization’s ongoing revision of its guidelines for evaluation of biosimilars. Baldrighi was a presenter on the topic at the recent Terrapinn Festival of Biologics meeting in Basel, Switzerland.
The WHO’s revisions will help to clarify the evidence requirements that developers of “similar biological products,” or biosimilars, should aim to satisfy when developing these molecules. Regulatory authorities in the United States and the European Union are moving toward a streamlined or clinical trial (CT) “tailored approach” that allows biosimilar developers to focus on the most advanced analytical technologies for characterization of biosimilars (ie, ensuring equivalence with reference drug molecules) and avoid comparative clinical trials that are not as precise and contribute little, if anything, to the sum of significant evidence for judging equivalence between highly similar biologic medicines.
The WHO, in conducting this review process, is moving in step with advances in the United States and European Union and providing an implied endorsement of CT tailoring. Following a public comment period this year, the WHO in November 2021 released the second draft of the guidance, Baldrighi explains.
The inclusion of CT tailoring holds out significant potential for adding constructive flexibility to biosimilar development that could make it more achievable for manufacturers to develop orphan biosimilars (for rare diseases) and other types of molecules that, owing to prior regulatory standards, may have been too costly to produce, Baldrighi says.
Advanced molecular characterization techniques lower the cost of biosimilar development and can substitute for in-human clinical trials that may be difficult or impossible for companies to perform in cases where patients with these diseases or conditions are scarce, she explains.
The WHO is not a regulator in the sense that it reviews and authorizes investigational medicines for use, but it maintains a list of essential medicines that it judges are qualified for safe and efficacious use, and its recommended medicines are adopted by medical authorities and countries worldwide. These guidelines on evaluation of biosimilar medicines will provide biosimilar developers with the assurance that the evidence basis upon which their molecules are founded will be satisfactory to the WHO when it decides what medicines to endorse.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Review Calls for Path to Global Harmonization of Biosimilar Development Regulations
March 17th 2025Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite challenges posed by differing national requirements and regulatory frameworks, according to review authors.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
From Amjevita to Zarxio: A Decade of US Biosimilar Approvals
March 6th 2025Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 originators—though the journey has been anything but smooth, with adoption facing hurdles along the way.